Similar articles

• Effects of tamoxifen on the levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin (PRL), 17 beta-oestradiol (E2), total and free testosterone (T) and total and free dihydrotestosterone (DHT) in blood of patients with benign prostatic hyperplasia.

  Stahl F, Schnorr D, Rohde W, Poppe I, Geier T, Dörner G. Stahl F, et al. Exp Clin Endocrinol. 1983 Jul;82(1):21-8. doi: 10.1055/s-0029-1210251. Exp Clin Endocrinol. 1983. PMID: 6193975
• Testosterone levels in benign prostatic hypertrophy and prostate cancer.

  Mearini L, Costantini E, Zucchi A, Mearini E, Bini V, Cottini E, Porena M. Mearini L, et al. Urol Int. 2008;80(2):134-40. doi: 10.1159/000112602. Epub 2008 Mar 19. Urol Int. 2008. PMID: 18362481
• Serum levels of follicle stimulating hormone, luteinizing hormone, prolactin, testosterone, 5 alpha-dihydrotestosterone, 5 alpha-androstane-3 alpha, 17 beta-diol, 5 alpha-androstane-3 beta, 17 beta-diol, and 17 beta-estradiol from male beagles with spontaneous or induced benign prostatic hyperplasia.

  Cochran RC, Ewing LL, Niswender GD. Cochran RC, et al. Invest Urol. 1981 Nov;19(3):142-7. Invest Urol. 1981. PMID: 6170603
• Prostatic cancer.

  Blacklock NJ. Blacklock NJ. Urol Res. 1977;5(1):1-5. doi: 10.1007/BF00257109. Urol Res. 1977. PMID: 324081 Review. No abstract available.
• Medical and nonmedical therapies for benign prostatic hypertrophy.

  Loughlin KR. Loughlin KR. Geriatrics. 1991 Jun;46(6):26-31, 34. Geriatrics. 1991. PMID: 1710196 Review.